Radius Health: A Biotech Stock Worth Buying Now?

NASDAQ: RDUS | Radius Health, Inc. News, Ratings, and Charts

RDUS – With continuing investments in research and development to extend human lifespans and improve the quality of life, the biotech industry looks poised for growth. RDUS is a fundamentally strong player in this space. So, let’s discuss if it is wise to bet on the name amid the current market volatility. Read on.

Radius Health, Inc. (RDUS) in Waltham, Mass., is a biopharmaceutical company that is focused on addressing unmet medical needs in bone health, orphan diseases, and oncology. Its lead product, TYMLOS, is an abaloparatide injection to treat postmenopausal women with osteoporosis at high risk for fracture.

The COVID-19 pandemic has highlighted the limitations of global healthcare. Biotechnology stocks have garnered significant investor interest since the onset of the public health crisis due to these companies’ role in developing treatments and vaccines to fight the virus. Furthermore, scientific breakthroughs in biotechnology have enabled new ways of treating and preventing diseases. And according to a Precedence Research report, the biotechnology market is expected to reach $1.68 trillion by 2030, growing at a 8.7% CAGR. Given RDUS’ strong fundamentals, we think it is well-positioned to capitalize on the industry’s solid growth prospects.

The stock has gained 31.4% in price over the past three months and 20.8% year-to-date to close the last trading session at $8.36.

Click here to checkout our Healthcare Sector Report for 2022

Here is what could influence RDUS’ performance in the upcoming months:

Robust Financials

RDUS’ total revenue increased 3.7% year-over-year to $65.10 million for the fourth quarter, ended Dec. 31, 2021. The company’s loss from operations narrowed 17.2% year-over-year to $11.76 million. Also, its net loss narrowed 27.1% year-over-year to $15.58 million. In addition, its adjusted EBITDA loss narrowed 71.4% year-over-year to $2.39 million.

Favorable Analyst Estimates

Analysts expect RDUS’ EPS for its fiscal year 2023 to increase 1,766.7% and 13%, respectively, year-over-year to $0.50 and $280.67 million. Its EPS is expected to grow 29.6% per annum over the next five years. Furthermore, Wall Street analysts expect the stock to hit $11.67 in the near term, indicating a potential 39.5% upside.

High Profitability

In terms of trailing-12-month gross profit margin, RDUS’ 92.02% is higher than the 55.47% industry average. Furthermore, its 4.43% trailing-12-month levered FCF compares with a negative industry average.

Reasonable Valuations

In terms of forward EV/S, RDUS’ 2.55x is 43.1% lower than the 4.49x industry average. Likewise, its 1.59x forward P/S is 68.8% lower than the 5.11x industry average.

POWR Ratings Show Promise

RDUS has an overall B rating, which equates to a Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. RDUS has a B grade for Growth. This is justified given its revenue and earnings growth estimates.

RDUS also has a B grade for Quality, which is consistent with its 1.23% trailing-12-month asset turnover ratio, which is 259.6% higher than the 0.34% industry average.

Furthermore, it has a B grade for Value, which is in sync with its 1.59x forward P/S, which is 68.8% lower than the 5.11x industry average.

RDUS is ranked #32 among 173 stocks in the Medical – Pharmaceuticals industry. Click here to access RDUS’ ratings for Momentum, Stability, and Sentiment.

Note that RDUS is one of the few stocks handpicked by our Chief Growth Strategist, Jaimini Desai, currently in the POWR Stocks Under $10 portfolio. Learn more here.

Bottom Line

With growing investments in research and development, the biotech industry is poised for growth. So, we think it could be wise to bet on RDUS given its higher than industry profitability, reasonable valuation, and revenue and earnings growth prospects.

How Does Radius Health, Inc. (RDUS) Stack Up Against its Peers?

RDUS has an overall POWR Ratings of B. One could also check out these other stocks within the Medical – Pharmaceuticals industry with an A (Strong Buy) rating: Novartis AG (NVS), Johnson & Johnson (JNJ), and Merck & Co., Inc. (MRK).

Click here to checkout our Healthcare Sector Report for 2022

What To Do Next?

If you would like to see more top stocks under $10, then you should check out our free special report:

3 Stocks to DOUBLE This Year

What gives these stocks the right stuff to become big winners?

First, because they are all low-priced companies with explosive growth potential, that excel in key areas of growth, sentiment and momentum.

But even more important is that they are all top Buy rated stocks according to our coveted POWR Ratings system, Yes, that same system where top-rated stocks have averaged a +31.10% annual return.

Click below now to see these 3 exciting stocks which could double (or more!) in the year ahead:

3 Stocks to DOUBLE This Year

 

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


RDUS shares were trading at $8.69 per share on Wednesday morning, up $0.33 (+3.95%). Year-to-date, RDUS has gained 25.58%, versus a -7.43% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
RDUSGet RatingGet RatingGet Rating
NVSGet RatingGet RatingGet Rating
JNJGet RatingGet RatingGet Rating
MRKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


How Much Resistance @ 6,000 for Stocks?

The post-election rally was an exciting burst for the stock market. With that the S&P 500 (SPY) made new highs just above 6,000. Since then stocks have struggled begging the question: what happens next? 44 year investing veteran Steve Reitmeister provides the answers along with his top 11 stocks to buy now.

3 Streaming Stocks Benefiting from Cord-Cutting Trends

As streaming continues to dominate the digital entertainment landscape, the global streaming market presents a lucrative investment opportunity. So, it could be ideal to invest in fundamentally solid streaming stocks Netflix (NFLX), Walt Disney (DIS), and Roku (ROKU). Read further...

3 Gold Stocks to Buy as Safe-Haven Demand Grows

Gold is a stable investment now due to its role as a safe-haven asset during economic uncertainty, rising demand, industrial use, and growth, bolstered by central bank purchases and interest rate cuts. Therefore, investors should consider investing in top gold stocks such as Newmont (NEM), Barrick Gold (GOLD), and Agnico Eagle Mines (AEM). Read more...

3 AI Stocks Transforming Industries and Driving Future Growth

With rapid digitalization, rapid adoption, and development, as well as surging demand, the AI market is on the rise. Amid this backdrop, investors could buy fundamentally solid AI stocks NVIDIA Corporation (NVDA), Microsoft (MSFT), and Meta Platforms (META) poised for substantial gains. Continue reading...

Does Trump Change Stock Market Outlook?

The rally of the S&P 500 (SPY) after the election gives a sense that investors are happy that Trump was elected. But perhaps there is more to this story than meets the eye. That’s why Steve Reitmeister shares his updated market outlook taking into account the pros and cons of Trumps proposed new policies. This comes with a preview of his top 11 stocks to buy now.

Read More Stories

More Radius Health, Inc. (RDUS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All RDUS News